Breaking News, Collaborations & Alliances

Ligand Earns SAGE Milestone

Initiates Phase III Trial

Ligand Pharmaceuticalshas earned a $500,000 milestone payment from SAGE Therapeutics relating to the initiation of SAGE’s Phase III study to evaluate the safety of SAGE-547 in patients with super-refractory status epilepticus (SRSE).
 
Results from this trial, along with results from SAGE’s planned Phase III placebo-controlled trial, and other clinical data from the SAGE-547 development program will be used for an New Drug Application (NDA) submission. 
 
Ligand entered into a Captisol license agreement with SAGE for the development and commercialization of SAGE-547 in 2011. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters